Tags

Type your tag names separated by a space and hit enter

[Enzyme-linked immunosorbent assay for antibodies against core protein of hepatitis C virus with a synthetic oligopeptide].
Fukuoka Igaku Zasshi. 1993 Apr; 84(4):148-58.FI

Abstract

An ELISA using N14E plus #19-#40, a synthetic peptide of the HCV core for the purpose of improving diagnosis of the HCV infection was studied to evaluate its usefulness in comparison with the tests of C100-3 antibody, N14 antibody and HCV EIA II. N14E plus #19-#40 is made up of 34 amino acids, containing the first two hydrophilic regions of HCV core forming epitopes. By using N14E plus #19-#40 antibody, HCV-antibody was detected in 94.4% of chronic hepatitis, 80.6% of liver cirrhosis and 87.5% of hepatocellular carcinoma of non-A non-B chronic liver diseases. This assay seems to be more sensitive than the assays of C100-3 antibody and N14 as far as tested for our patients in this district. In chronic liver diseases, 5.6% (5/90) of patients negative for HCV EIA II were positive to anti-N14E plus #19-#40; one of these 5 patients was HCV RNA positive. Anti-N14E plus #19-#40 was detected in 57.5% out of 40 paid blood donors with elevated ALT higher than 50IU and negative for HBsAg, C100-3 and N14, but positive for HCV RNA. The results suggest that anti-N14E plus #19-#40 as well as HCV EIA II seems to be useful for the detection of patients with the HCV infection and that an improvement for the diagnosis of type C hepatitis and a decrease in the incidence of type C post-transfusion hepatitis can be achieved by using anti-N14E plus #19-#40.

Authors+Show Affiliations

Second Department of Internal Medicine, Faculty of Medicine, Kagoshima University.

Pub Type(s)

English Abstract
Journal Article

Language

jpn

PubMed ID

7686127

Citation

Sugiyasu, T. "[Enzyme-linked Immunosorbent Assay for Antibodies Against Core Protein of Hepatitis C Virus With a Synthetic Oligopeptide]." Fukuoka Igaku Zasshi = Hukuoka Acta Medica, vol. 84, no. 4, 1993, pp. 148-58.
Sugiyasu T. [Enzyme-linked immunosorbent assay for antibodies against core protein of hepatitis C virus with a synthetic oligopeptide]. Fukuoka Igaku Zasshi. 1993;84(4):148-58.
Sugiyasu, T. (1993). [Enzyme-linked immunosorbent assay for antibodies against core protein of hepatitis C virus with a synthetic oligopeptide]. Fukuoka Igaku Zasshi = Hukuoka Acta Medica, 84(4), 148-58.
Sugiyasu T. [Enzyme-linked Immunosorbent Assay for Antibodies Against Core Protein of Hepatitis C Virus With a Synthetic Oligopeptide]. Fukuoka Igaku Zasshi. 1993;84(4):148-58. PubMed PMID: 7686127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Enzyme-linked immunosorbent assay for antibodies against core protein of hepatitis C virus with a synthetic oligopeptide]. A1 - Sugiyasu,T, PY - 1993/4/1/pubmed PY - 1993/4/1/medline PY - 1993/4/1/entrez SP - 148 EP - 58 JF - Fukuoka igaku zasshi = Hukuoka acta medica JO - Fukuoka Igaku Zasshi VL - 84 IS - 4 N2 - An ELISA using N14E plus #19-#40, a synthetic peptide of the HCV core for the purpose of improving diagnosis of the HCV infection was studied to evaluate its usefulness in comparison with the tests of C100-3 antibody, N14 antibody and HCV EIA II. N14E plus #19-#40 is made up of 34 amino acids, containing the first two hydrophilic regions of HCV core forming epitopes. By using N14E plus #19-#40 antibody, HCV-antibody was detected in 94.4% of chronic hepatitis, 80.6% of liver cirrhosis and 87.5% of hepatocellular carcinoma of non-A non-B chronic liver diseases. This assay seems to be more sensitive than the assays of C100-3 antibody and N14 as far as tested for our patients in this district. In chronic liver diseases, 5.6% (5/90) of patients negative for HCV EIA II were positive to anti-N14E plus #19-#40; one of these 5 patients was HCV RNA positive. Anti-N14E plus #19-#40 was detected in 57.5% out of 40 paid blood donors with elevated ALT higher than 50IU and negative for HBsAg, C100-3 and N14, but positive for HCV RNA. The results suggest that anti-N14E plus #19-#40 as well as HCV EIA II seems to be useful for the detection of patients with the HCV infection and that an improvement for the diagnosis of type C hepatitis and a decrease in the incidence of type C post-transfusion hepatitis can be achieved by using anti-N14E plus #19-#40. SN - 0016-254X UR - https://www.unboundmedicine.com/medline/citation/7686127/[Enzyme_linked_immunosorbent_assay_for_antibodies_against_core_protein_of_hepatitis_C_virus_with_a_synthetic_oligopeptide]_ L2 - http://www.diseaseinfosearch.org/result/3332 DB - PRIME DP - Unbound Medicine ER -